GlassScriptPhysician profile
Inbok Wee
NPI 1740900687
$1,631.19
in general payments reported to CMS, 2019-2025
20 companies · $718 in 2025
The $718 reported for 2025 was more than what 81% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $43.10 · 2023: $368 · 2024: $502 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.33 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.47 | 2024-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $120.96 | 2023-2025 | |
| Exact Sciences Corporation | $104.02 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $101.23 | 2023-2025 | Jardiance, Mounjaro |
| Shield Therapeutics INC | $92.56 | 2023-2024 | Accrufer |
| Pfizer INC. | $81.12 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $63.79 | 2023 | Xarelto |
| Glaxosmithkline, LLC. | $61.56 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $58.08 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.74 | 2024 | Xifaxan, Trulance |
| Amgen INC. | $49.51 | 2023-2024 | Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $44.37 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $36.83 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $24.92 | 2024 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.42 | 2025 | Gemtesa |
| Gilead Sciences, INC. | $23.79 | 2023 | |
| Lundbeck LLC | $23.67 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $23.45 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $19.37 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inbok Wee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.